Volumes : Issues : Articles

Cancer Watch 2000
Cancer Watch 2001
Cancer Watch 2002
Cancer Watch 2003
Cancer Watch 2004
Cancer Watch 2005
Cancer Watch 2006
Cancer Watch 2007
Cancer Watch 2008
Cancer Watch 2009
Cancer Watch 2010
Cancer Watch 2011
Cancer Watch 2012

CW August 2004

Volume 13
Issue Number 8
August 2004
ISSN 10593802

A Novel HSP90 Inhibitor Enters Phase I Study

Conforma Therapeutics initiates two Phase I studies of HSP90 inhibitor CNF 1010 in patients with solid tumors and chronic myelogenous leukemia (CML).
Go to Previous Page
Go to Next Page

Source & Additional Reading

Lawrence C. Fritz, President and chief executive officer of Conforma.

Purchase Downloadable Full-text PDF of Article: $10.00

Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details.

Download Complete Issue CW August 2004

Purchase Downloadable Full-text PDF of Complete Issue: $20.00

<< Go Back to CW August 2004